The Systemic Inflammatory Response Syndrome in Patients With ST-Segment Elevation Myocardial Infarction*
Синдром системной воспалительной реакции у пациентов с инфарктом миокарда с подъемом сегмента ST*
2013-06-12
SCID: 54.1/m4rfcghy
Discuss with AI
90-day mortalityST-segment elevation myocardial infarctionmechanical reperfusionmulticenter randomized controlled trialssystemic inflammatory response syndrome
Figures from the paper
Abstract (AI)
OBJECTIVES: To assess whether systemic inflammatory response syndrome is associated with morbidity and mortality in ST-elevation myocardial infarction. DESIGN AND SETTING: Secondary analysis of multicenter randomized controlled trials. PATIENTS: Complement and reduction of infarct size after angioplasty or lytics project patients (n=1,903) with ST-elevation myocardial infarction undergoing fibrinolysis or mechanical reperfusion. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The prevalence of systemic inflammatory response syndrome was described in the 1,186 patients (64.4%) with data available for all systemic inflammatory response syndrome criteria. Using multiple imputations for the 1,843 patients (96.8%) with available endpoints, we compared the 90-day prevalence of death, shock, heart failure, or stroke between patients with and without systemic inflammatory response syndrome at presentation and at 24 hours post admission. Systemic inflammatory response syndrome was defined as ≥2 of 1) heart rate>90 beats/min, 2) respiratory rate>20 breaths/min, 3) body temperature>38 or <36°C, or 4) leukocyte count>12 or<4×10/L. At presentation, 25.0% of patients met systemic inflammatory response syndrome criteria; at 24 hours, 8.1% of patients met systemic inflammatory response syndrome criteria. The primary outcome was more frequent among patients with systemic inflammatory response syndrome at presentation (31.0% vs 16.7%; adjusted hazard ratio, 1.78 [95% CI, 1.35-2.34]; p<0.001) and at 24 hours (36.7% vs 11.1%; adjusted hazard ratio, 2.84 [95% CI, 2.03-3.97]; p<0.001). Mortality at 90 days was also higher among patients with systemic inflammatory response syndrome at either time point. Each additional systemic inflammatory response syndrome criterion was independently associated with 90-day outcomes at the time of presentation (adjusted hazard ratio, 1.41 per systemic inflammatory response syndrome criteria [95% CI, 1.24-1.61]; p<0.001) and at 24 hours (adjusted hazard ratio, 1.72 per systemic inflammatory response syndrome criteria [95% CI, 1.47-2.01]; p<0.001). CONCLUSION: The diagnosis of systemic inflammatory response syndrome and the cumulative number of systemic inflammatory response syndrome criteria were independently associated with 90-day clinical outcomes in a population of patients with ST-elevation myocardial infarction. The independent association of this simple composite measure of the inflammatory response with outcomes underscores the importance of the clinical inflammatory response in ST-elevation myocardial infarction.
Key Findings
1
Each additional SIRS criterion independently increased the risk of 90-day adverse outcomes at presentation and 24 hours.
2
Ninety-day mortality was higher among patients meeting SIRS criteria at presentation or 24 hours.
3
SIRS at 24 hours was associated with an even greater risk of the primary outcome: 36.7% versus 11.1%; adjusted hazard ratio, 2.84.
4
SIRS at presentation was associated with higher 90-day death, shock, heart failure, or stroke: 31.0% versus 16.7%; adjusted hazard ratio, 1.78.
5
Systemic inflammatory response syndrome was present in 25.0% of patients at presentation and 8.1% at 24 hours after admission.
Research Object
Patients with ST-segment elevation myocardial infarction undergoing fibrinolysis or mechanical reperfusion
Research Subject
The association of systemic inflammatory response syndrome at presentation and 24 hours with 90-day morbidity and mortality
Publication Details
Publication Date
2013-06-12
Journal
Publisher
ISSN
Access Type
Author Information
Download PDF
Subscribe to digest